Landec Corporation provided consolidated revenue guidance for full year fiscal 2022. For full year fiscal 2022, the company expected consolidated revenues: range of $179 million to $185 million (+4% to +8%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.89 USD | -5.05% |
|
-10.11% | -21.00% |
Jun. 11 | 22NW Fund Submits Shareholder Proposals to Lifecore Biomedical | CI |
May. 20 | 22NW Fund Nominates Candidates to the Board of Lifecore Biomedical | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.00% | 149M | |
+52.93% | 803B | |
+40.98% | 629B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.42% | 244B | |
+2.17% | 226B | |
+10.66% | 215B | |
+6.24% | 164B |
- Stock Market
- Equities
- LFCR Stock
- News Lifecore Biomedical, Inc.
- Landec Corporation Provides Consolidated Revenue Guidance for Full Year Fiscal 2022